In a report published Friday, Jefferies & Company reiterated its Buy rating on Onyx Pharmaceuticals ONXX, and raised its price target from $101.00 to $103.00.
Jefferies noted, “ONXX reported a strong Kyprolis U.S. sales launch w/ $19M in only 8 wks into the launch (v. JEF: $3M), citing contributing factors such as pre-identification of pts prior to launch, and Kyprolis as the first tx in the salvage setting serving an unmet medical need. As a result we have adjusted our 2012-2013 Kyprolis revenues and raised our PT to $103 from $101, and reiterate our Buy.”
Onyx Pharmaceuticals closed on Thursday at $80.33.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in